New proton beam combo aims to shrink esophageal tumors before surgery

NCT ID NCT02213497

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new approach for people with locally advanced esophageal cancer. Before surgery, patients receive proton beam radiotherapy along with two chemotherapy drugs (carboplatin and paclitaxel). The main goal is to find the safest dose and see how well patients tolerate the combination. Only 30 participants are enrolled, so the focus is on safety, not yet on cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Proton beam radiotherapy combined with carboplatin and paclitaxel chemotherapy
What this could lead to
If successful, this could lead to a safer and more effective way to shrink esophageal tumors before surgery, potentially improving outcomes.
What could go wrong
This is an early phase 1 trial with only 30 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects from the combined treatment may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.